PTC Therapeutics Inc (PTCT) Exchange: NASDAQ

PTC Therapeutics, Inc. (PTCT) is an American biopharmaceutical company developing treatments for rare genetic diseases, including Duchenne muscular dystrophy. PTC is a leader in researching, developing, and manufacturing treatments that target the messenger ribonucleic acid (mRNA) pathways within the body. The company first embarked on its mission in 1998 and has grown rapidly in size and influence within the pharmaceutical and biotechnological industry. PTC has a presence in over 25 countries, both in terms of research and its numerous subsidiaries across Europe and Asia. This large multinational firm employs over 450 individuals in its different arms across the world — including its research division, which operates out of its headquarters in South Plainfield, NJ. It also maintains an elite roster of specialist advisors to help guide its research and development in precision medicine solutions. In 2018, PTC completed its acquisition of Agilis Biotherapeutics and made two distinct advances for two gene therapy programs for rare diseases. 2019 saw numerous other successes such as its FDA approval for Waylivra, the world’s first oral medication for the treatment of familial chylomicronemia syndrome. PTC’s dedication to rare and genetic diseases has made it into one of the most important organizations in precision medicine. It has a long list of strategic partners and alliances that have been established to make sure that PTC’s technology is at the forefront of biopharmaceutical research. Its groundbreaking work in the field ensures that PTC will remain an influential figure in the years to come.